Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2017
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202N Lynn Henry, Joseph M Unger, Anne F Schott, et al.Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.Science Translational Medicine|November 1, 2016
Cancer cells induce metastasis-supporting neutrophil extracellular DNA trapsJuwon Park, Robert W Wysocki, Zohreh Amoozgar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222Halle C F Moore, William E Barlow, George Somlo, et al.Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.Cancer Research|December 14, 2017
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance MechanismsCostanza Paoletti, Andi K Cani, Jose M Larios, et al.Pageof 6